Natera is preparing for the pace of its prospective study readouts to "accelerate meaningfully" over the next few years to potentially demonstrate the clinical utility of its Signatera test, company ...

The company also submitted a request for a CLIA waiver for the test, which would permit its use in decentralized testing locations.

The technology supports the adoption of digital pathology and artificial intelligence in cancer diagnostics by enabling greater consistency in laboratory slide staining.

Cancer early detection firm Grail said after the close of the market Wednesday that its second-quarter revenue grew 26 percent year over year, noting that it is preparing for an expected advisory ...

The test received PDMA approval for colorectal cancer in June, making it the country's first PMDA-approved MRD test.

The firm also offered updates on its autoimmune disease, newborn screening, and other specialty diagnostics businesses from the sidelines of the conference.

The firm raised its full-year 2026 revenue guidance to a new range of $6.42 billion to $6.48 billion from prior guidance of $6.41 billion to $6.46 billion.

The issue of developing pediatric reference intervals for common laboratory tests has been one of the organization's priorities.

Executives disclosed new directions in neurodegenerative disease testing and low-volume sample collection for high-volume testing.

The ELISA-based CIZ1B Biomarker Blood Test for Lung Cancer is designed to detect the lung cancer-produced biomarker CIZ1B. It was developed by UK-based Cizzle Biotechnology, which licensed it in the ...

Genprex plans to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies, while Roche will validate assays using its TROP2 antibody.